CLIENT LOGIN
Investors2022-08-04T10:36:13-07:00
FOR INVESTORS

News, events, and reports.


Investor Presentations

Recent Healthcare Conferences

View our presentations

Scientific Evidence

MammaPrint and BluePrint Utility

View our Landmark Trials

Reach out to our investor relations department.

Contact Us

Recent Events & News

Healthcare Conferences

Agendia’s leadership team presents at healthcare conferences globally to share updates on the company and our vision for how we fit into the breast cancer treatment space

View Presentations Here

MINDACT Update

Long term follow up data for the EORTC’s landmark MINDACT trial were presented at major conferences in 2020 and confirm MammaPrint’s utility for women with breast cancer

View Data Here

NBRST Update

Five-year follow up data for Agendia’s prospective NBRST trial were presented at SABCS 2020 and confirm the utility of our tests for pre-operative treatment planning

View Data Here

SABCS 2020

Agendia will present new data from ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming […]

View More Information
Two women reading about genomic breast cancer results

Latest News

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

Read The Article
I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

View The Project

Investor News

1503, 2022

Agendia Appoints Elizabeth Hanna as Executive Vice President and Chief Commercial Officer, Bolsters Company’s Global Market Growth Strategy

March 15th, 2022|

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 15, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced the appointment of global commercial leader Elizabeth (Betsy) Hanna as Executive Vice President and Chief Commercial Officer, effective March 15, 2022. “We are pleased to welcome Betsy as a critical member of our executive team. Betsy is a distinguished global healthcare and biotech executive with a proven track record building market value in medical device and diagnostic businesses in the US and globally,” said Mark Straley, Chief Executive Officer of Agendia. “Her extensive functional Read More

1303, 2022

GenomeWeb – Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market

March 13th, 2022|

January 27, 2022 By Leo O’Connor NEW YORK ─ As part of its effort to gain regulatory clearance in the US and beyond, Agendia has begun offering early access to a digital testing platform for patients in Brazil that allows physicians to receive genomic insights from a digitized image of a tumor to predict the likelihood of metastasis in early-stage breast cancer. The rollout aligns with Agendia's long-term goal to achieve broad, global adoption for tests in its pipeline and provide results from a hematoxylin and eosin (H&E) stain that are equivalent to the information provided by its current microarray-based MammaPrint assay, the firm said. The new digital assay, called Digital MammaPrint, uses artificial intelligence technology developed thorough a collaboration between Agendia and New Read More

702, 2022

Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment

February 7th, 2022|

New analysis in peer-reviewed journal Genes, Chromosomes and Cancer further establishes that MammaPrint and BluePrint both comprehensively represent and capture the 10 hallmarks of cancer in early-stage breast cancer Study validates genomic basis of MammaPrint High 2 category for breast cancer tumors, shows genomic testing can provide further details into biological significance and clinical behavior IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 7, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced new data published in Genes, Chromosomes and Cancer (Genes) that show MammaPrint® and BluePrint® gene signatures represent and Read More

1201, 2022

Agendia to Provide First Digital MammaPrint Capability to Brazil

January 12th, 2022|

AI solution will expand Agendia’s testing platform in the Brazilian breast cancer market Digital MammaPrint offers fast turnaround time to molecular diagnostics, delivering actionable information to physicians treating patients with breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 12, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced that it is offering early access to its Digital MammaPrint platform for patients with breast cancer in Brazil, expanding the company’s offerings in the country with the goal of bringing essential information from cancer testing to the larger global breast cancer community. Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from Read More

1001, 2022

Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

January 10th, 2022|

Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing, to bring improved insights to patients with breast cancer globally IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 10, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina’s approach to IVD partnerships in oncology. Agendia joins Illumina’s growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection, and other applications. Illumina and Agendia Read More

601, 2022

Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum

January 6th, 2022|

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 6, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS and Scott Mendel, MBA to the Company’s Board of Directors. “We are pleased to be expanding Agendia’s Board of Directors with the appointment of two accomplished industry executives,” said Mark Straley, Chief Executive Officer of Agendia. “With combined decades of leadership and results-driven performance, Suja and Scott will provide Agendia with invaluable guidance, informed by extensive executive experience. As we continue to deliver on our goal to provide crucial genomic information to physicians and their patients to improve care, we look forward to tapping into Read More

Go to Top